Octozi has raised $3 million in seed funding to expand its agentic AI platform for clinical development, a space where drug makers still spend huge time on manual data work. The New York-based startup says its software helps sponsors automate data cleaning, review, reconciliation, and reporting across clinical trials.markets. The funding round was led by Surface Ventures, with participation from Remarkable Ventures. It also followed an earlier investment from Debiopharm’s venture arm, showing continued interest from investors focused on life sciences and pharma operations.
Clinical development is slow and expensive because trial teams must check large volumes of patient data and fix errors before a study can move forward. Octozi says its human-in-the-loop system keeps experts in control while AI speeds up routine work and reduces mistakes.
The company says its platform already supports Phase III trials, which are late-stage studies involving thousands of patients. In a controlled study, Octozi claimed its AI increased data cleaning throughput about six times, cut reviewer error rates from 54.7% to 8.5%, and lowered false positive queries about 15 times.
Octozi also said a model trial analysis pointed to savings of more than $5 million per Phase III oncology trial. That makes the startup attractive to pharma sponsors and contract research organizations that want faster timelines and lower operating costs.
This funding comes at a time when healthcare AI startups are gaining attention for solving specific industry bottlenecks. Octozi is trying to stand out by focusing on one of the most difficult parts of drug development: turning raw trial data into clean, usable, and regulation-ready information.
FAQs [Frequently Asked Questions]
1. What does Octozi do?
Octozi builds agentic AI tools that automate clinical trial data cleaning, review, reconciliation, and reporting for pharmaceutical sponsors and research teams.
2. Who invested in the seed round?
Surface Ventures led the $3 million seed round. Remarkable Ventures also joined, along with support linked to Debiopharm’s earlier investment.
3. How much time or money can Octozi save?
Octozi said its AI can cut manual work sharply, improve accuracy, and may save more than $5 million per Phase III oncology trial.